The role of polymorphic allelic variants of the VEGFα and TGFβ gene in the development of cerebrovascular disorders in patients with metabolic syndrome
Objective: The aim of the study was to understand the link between the VEGFα and TGFβ genes in the development of stroke in patients with…Sensitive biomarker of Parkinson’s disease linked to mutations in the glucocerebrosidase gene
Objective: To find a biomarker for development of Parkinson’s disease (PD) in carriers of mutations in the glucocerebrosidase gene (GBA). Background: Mutations in the GBA…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Correlation and comparison of the lipid profile and the body fat mass in people with Parkinson’s disease submitted to three physical therapies
Objective: To correlate and to compare changes on the lipid profile (LP) and on the body fat mass in people with Parkinson's disease (PD) submitted…Post mortem fatty acid abnormalities in the cerebellar cortex of patients with essential tremor
Objective: The objective of the study was to compare fatty acids (FA) profiles within different fractions of phospholipids retrieved from the cerebellum of patients who…Abnormal Gait in Cerebrotendenious Xanthomatosis a case report
Objective: To identify patients with Cererotendenious xanthomatosis. To present the neurological spectrum of the disease. Background: Cerebrotendenious xanthomatosis is a rare lipid storage disease due…Cerebrotendinous Xanthomatosis presenting Parkinsonism with bilateral iron accumulation in the basal ganglia
Objective: Cerebrontendinous xanthomatosis(CTX) is a treatable, autosomal recessive, lipid storage disorder disease. Herein, we present a case of CTX. It aims to refresh and improve…Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development
Objective: To study alterations in urinary phospholipids as biomarkers of LRRK2 mutations and Parkinson’s disease (PD) status. Background: LRRK2 mutations are a common cause of…Profiling of lipoproteins and associated lipids in serum samples from Idiopathic REM Sleep Behavior Disorder patients to identify biomarkers for Parkinson’s disease
Objective: To perform a lipidomic profile in serum samples from IRBD patients collected before and after their conversion to PD and DLB, in order to…Metabolomic Analysis of Fecal Matter from Parkinsonian Mice
Objective: Assess the metabolic changes in fecal matter in mice treated with an immunomodulatory therapy. Background: The cause of neuronal death in Parkinson’s disease (PD)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.